The physiological effects of natural compounds that dual-modify GLP-1 signaling and the TXNIP–thioredoxin pathway have been confirmed by animal research, especially employing rat models of MetS, type 2 diabetes, or diet-induced obesity [72]. Here, TXN is linked to metabolic syndrome.